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Abstract 
The purpose of this review is to assess whether or not economic evaluation studies published in PharmacoEconomics in 2015 meet 
the standards of normal science. Two questions are key to the assessment: (i) did the authors attempt to generate testable claims as 
to the impact of the pharmaceutical product in health care systems and (ii) did the authors suggest how the claims might be 
evaluated? A total of 31 studies were evaluated, including 14 research articles, 8 systematic reviews and 9 reviews. Although the 
majority of the studies met recommended standards for cost-effectiveness analysis, none met the standards of normal science. They 
were best categorized as imaginary worlds or thought experiments. The reader has no idea whether the claims for the products are 
right or even if they were wrong. Journal editors have two options: (i) require authors to submit cost-effectiveness claims that are 
evaluable with a protocol suggesting how the claim may be evaluated or (ii) continue to publish non-evaluable cost-effectiveness 
claims but insist authors indicate that the claims are non-evaluable. 
 
 
Introductions 
A number of recent publications have raised doubts as to the 
status of modeled cost-effectiveness claims in 
pharmacoeconomics 1  2  3  4.   The primary concern has been 
with the construction of modeled thought experiments (or 
imaginary worlds) to support claims for comparative cost-
effectiveness. Rather than the development of models to 
generate testable claims or predictions for the anticipated 
impact of new products and devices in health care systems, 
the modeled claims are seen as an end in themselves. 
Unfortunately, readers are not advised, as a matter of course, 
that non-evaluable cost-effectiveness claims should not be 
taken at face value.  
 
If a modeled claim is impossible to assess or if the model fails 
to generate testable claims, then the model fails to meet the 
standards of normal science.  These standards are absolute 
and have been recognized since the 17th century. The core 
elements being: (i) the construction of empirically evaluable 
coherent theories and (ii) the testing of hypotheses through 
experimentation or systematic observation.  
 
Empirical testability differentiates science from non-science or 
pseudoscience. Irrespective of whether or not the authors of a 
model argue that it is a reasonable reflection of reality, a 
correspondence that is sufficient and necessarily entails the 
claims made, the absence of testable claims means that the  
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model should be put to one side. This may involve a 
reconsideration of the model to assess whether or not it is 
capable of being recast to generate testable claims. If the 
model is incapable of generating testable claims then it should 
be rejected. 
 
In the absence of experimentation or observation, a formulary 
committee has no idea whether modeled claims are right or 
even if they are wrong. To an unknown and unknowable 
extent the claims may be misleading and even potentially 
harmful. Acceptance of the standards of normal science is in 
contrast, therefore, to a postmodern or relativist position 
which holds that if the model intends to reflect reality then, 
given the consensus view within the profession, we should 
accept the claims made and to factor them, even though they 
are impossible to evaluate, into formulary decisions. 
 
While a debate over philosophical positions may seem 
something of a stretch when we address issues of cost-
effectiveness modeling, the acceptability or otherwise of 
modeled claims is critical to an assessment of the worth of 
pharmacoeconomic modeling to support value claims. If we 
conclude that modeled yet untestable claims should be 
rejected as a basis for decision making, then we face the 
prospect of rejecting much of the modeling endeavors over 
the past 25 to 30 years as well as guidelines for good practice 
and recommendations for formulary submissions.  If we 
accept the relativist position that modeled claims, even if 
untestable, are still credible as thought experiments or 
imaginary worlds  then we run the risk of losing status as a 
‘science’ in our rejection of the standards of normal science 
that underpin our belief in the discovery of new facts.   
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The purpose of this review is to evaluate the cost-
effectiveness or economic evaluation studies that have been 
published in PharmacoEconomics in the period January 2015 
to December 2016. This evaluation is part of an ongoing 
program at the College of Pharmacy, University of Minnesota 
exploring the credibility of cost-effectiveness claims; to see 
whether published claims meet the standards for falsification 
and replication that are the core of the scientific method. 
 
Methods 
A systematic review, following the PRISMA-P checklist (MeSH 
terms ‘cost’, ‘cost-effectiveness’, ‘QALY’), of all papers 
published in PharmacoEconomics in the period  January 2015 
to December 2016 identified 31 economic evaluation studies 5. 
These comprised 14 original research articles, 8 systematic 
reviews and 9 reviews. These studies are detailed in Table 1. 
 
In order to judge whether the modeled claims presented or 
reviewed met the standards of normal science, four questions 
were considered: 
• Is the model capable of generating testable claims? 
• Did the author(s) attempt to generate testable 
claims? 
• Did the author(s) suggest how the claims might be 
evaluated? 
• Did the author(s) caution readers as to the 
implications of generating non-testable claims? 
 
A testable claim was defined as one that could be evaluated 
either experimentally or observationally in a timeframe 
relevant to the needs of a formulary committee (ideally a 
period of 2 to 3 years). This period was chosen because a 
testable claim was seen as provisional; a condition established 
in the WellPoint formulary guidelines issued almost a decade 
ago. 6  7 . A product or device could, in this context, be 
accepted by a formulary committee for provisional listing, but 
subject to an agreement with the manufacturer to report back 
to the committee with evidence to support the claims made. 
These claims could be for product comparative effectiveness, 
for the impact of the product on resource utilization or some 
combination of these to support a claim for incremental cost-
effectiveness. The claim for comparative effectiveness could 
encompass clinical endpoints as well as those captured as 
patient reported outcomes.   
 
The important point to note is that the modeled claims were 
not to be judged on the reasonableness or otherwise of the 
assumptions of the model; a point made recently by Ellis and 
Silk in reference to claims in string theory modeling 8. The fact 
that the claims could not be tested led to those supporting 
string theory to argue that  the inherent elegance of a model 
should be sufficient for its acceptance, without need to 
evaluate any testable claims. Ellis and Silk pointed out that this 
was unacceptable if the standards of normal science were to 
hold. 
 
Certainly a cost-effectiveness model would be expected to 
cover comparator products, or least the key comparators, and 
to identify the target population for the claims. But this does 
not mean a model should necessarily conform to 
recommended standards from organizations such as the 
International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) or to items such as the CHEERS checklist 9  10  
11  12  13. While the CHEERS checklist has been embraced by a 
number of journals, the point is that neither ISPOR 
recommended standards for good practice or the CHEERS 
checklist have endorsed the standards of normal science in 
accepting the central role of claims assessment. In this review 
there was no attempt to censor or categorize the studies 
reviewed by such criteria, although given that 
PharmacoEconomics subscribes to the CHEERS checklist, it was 
assumed that these criteria would have been addressed as 
part of the peer review process. 
 
In judging whether or not a model might support testable 
claims, even if the possibility was not considered by the 
authors(s), three characteristics of the model are important. 
These are (i) the modeling framework, (ii) the choice of 
primary outcome measure; and (iii) the time frame for the 
model.  A Markov or discreet event simulation model with a 
lifetime perspective and with discounted cost per quality 
adjusted life year (QALY) claims as the primary endpoints 
would be one that would be impossible to evaluate. Against 
this, a simple, trial-based decision model with a timeframe of 
12 to 18 months with claims expressed in clinical terms 
(including PROs) and resource utilization endpoints would, 
given access to readily available data sources in the US, be 
open to hypothesis testing and feedback to a formulary 
committee. 
 
In the case of the systematic reviews and reviews, the focus 
was on, not the individual papers but on the whether or not 
the reviewer took into account the issue of whether the 
models presented in the papers under review were capable of 
generating testable claims, whether any attempts were made 
to evaluate claims and whether the authors made any 
suggestions as to how the claims made might be evaluated by, 
for example, a formulary committee as part of ongoing disease 
area and therapeutic reviews. A number of these reviews 
utilized a checklist to evaluate the ‘quality’ of the study, such 
as the CHEERS or the Quality of Health Economics Studies 
(QHES) checklist 14. The QHES checklist does not consider 
either the ability to generate testable claims or proposals for 
how claims might be evaluated as part of a quality 
assessment.  
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A study may be judged ‘high quality’ by application of the 
QHES or CHEERS checklist but still may fail to meet the 
standards of normal science. It may meet the National 
Institute for Health and Care Excellence (NICE) reference case 
standards, but as a result fail to provide operational content in 
meeting the standards of normal science 15. Irrespective of the 
internal ‘mathematical elegance’ of the cost-effectiveness 
model, it would be considered by the standards of normal 
science to be what is described here as an imaginary world or 
thought experiment. 
 
Results 
Original Research Articles 
The primary outcome measure in 13 of the 14 original 
research articles was incremental cost-per-QALY. Subsidiary 
endpoints included costs, years of life gained and events 
avoided (e.g., falls). In a number of the articles discount rates 
were applied to both costs and outcomes to yield discounted 
cost-per-QALY claims. The majority of the papers, although 
not necessarily stating it explicitly, attempted to follow NICE 
reference case standards or those proposed by ISPOR for good 
modeling standards in generating estimates of direct medical 
costs and utilizing a generic QALY measure. None of the 
models utilized measures of generic QALYS generated directly 
from the comparative products’ RCTs. The only paper that 
reported cost-per-QALYs from a trial generated these 
indirectly from the SF-12v2 instrument utilized in the trial 24. 
Other studies mapped utility values from other instruments or 
captured utilities from studies in ‘similar’ product scenarios. 
 
With the exception of one paper, all utilized a Markov state-
transition model framework. The timeframes for the various 
state transition models ranged from 5 years to the lifetime of 
the modeled cohort. Seven of the articles employed a time 
frame of 30 years or longer (4 the lifetime of the cohort) and 4 
articles reported on a 10 year timeframe. In the case of the 
lifetime models, three of these focused on either older 
patients (with limited lifespans) or those whose health states 
were in the end stage of the disease. The youngest lifetime 
cohort at age 40 years was modeled for dermatomysotis, with 
56 years for hyperphosphataemia, 70 years for atrial 
fibrillation and 84 years for injury prevention.  
 
In respect of the questions raised for this review, none of the 
studies presented considered how the claims made might be 
evaluated. None of the studies presented testable claims.  
There were no discussions of how these modeled claims might 
be factored into formulary decisions. Discussions on the 
limitations of the studies focused on the deficiencies in the 
evidence base used to populate the model parameters, the 
presence of significant evidence gaps, the lack of direct 
generic QALY measures for the target populations, the 
difficulty of translating costs estimates across health systems 
and the degree of uncertainty attached to the modeled claims 
for comparative effectiveness.  
 
Systematic Reviews 
Five of the 8 systematic reviews utilized a quality assessment 
checklist to grade the individual studies: 3 papers used the 
CHEERS checklist while 3 utilized the QHES checklist. Zhang et 
al concluded that of the 53 studies evaluated in psoriasis the 
majority were of low quality. In their view high quality studies 
should apply a reasonably long time horizon (with 30% 
adopting a time horizon of < 1 year), adopt a valid and 
comparable effectiveness measure (QALY), consider all 
relevant cost items and conduct a sensitivity analysis 31. The 
question of whether or not the model should be capable of 
generating testable hypotheses was not considered. Hiligsman 
et al in their review of postmenopausal osteoporosis drugs 
also reported on an insufficient quality of reporting for several 
articles 30. These included methods for identifying and 
synthesizing clinical effectiveness data, the description of the 
population and methods used to value preference based 
outcomes (all but one of the studies used QALYs as the 
outcome measure)  and all analytic methods supporting the 
evaluation. Again, the question of whether or not the model 
should be capable of generating testable hypotheses was not 
considered. None of the reviews raised any questions as to the 
appropriateness of Markov models in generating testable 
predictions and the implications for evaluating model findings 
where, for example, the timelines of the models (9 out of 20 
Markov simulations modeled claims for 40 years or more). 
 
The most frequently cited outcomes were QALYs and life years 
gained (LYG). In postmenopausal osteoporosis, 38 out of 39 
studies used QALYs; in psoriasis PASI (Psoriasis Area and 
Severity Index) were reported in 26 studies and QALYs in 15 
studies (out of a total of 53 studies) 30; in diabetes all 11 
studies reported QALYs 34; in tuberculosis QALYs were the 
outcome measure in 15 studies and TB cases prevented in 7 
studies (out of 24 studies) 35; in gout the humanistic burden 
was reported as either generic or disease specific HRQoL 36; 
and in ovarian cancer, out of 28 studies,  15 studies reported 
cost per LYG and cost per QALY in 13 studies 38. Once again, 
the question of testable claims was not raised or even how 
differences in comparative cost-per-QALY claims within 
disease or therapeutic areas or for individual products across 
the various studies might be resolved. The issue of whether 
QALYs could actually be evaluated or their absence in 
administrative claims or other health data sets was not raised. 
Any comparison is made the more difficult, presumably, given 
the disparate instruments and matching (or crosswalking) 
techniques employed in generating utility scores. There was 
no discussion of how these disparities might be resolved. 
Review Articles 
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Eight of the 9 review articles reported the findings of NICE 
single technology appraisals (STA) 39  40  41  43  44  45  46  47 . Under 
the STA process manufacturers are invited to submit a clinical 
and cost-effectiveness case for a product in seeking a 
recommendation within its marketing authorization. The role 
of the Evidence Review Group (ERG) is to evaluate the 
submission, possibly seek additional input from the 
manufacturer, and if necessary develop its own model and 
report to the NICE Advisory Committee. The ERG report is 
considered by the NICE Appraisal Committee, with (after 
possibly further review) a final recommendation, and a NICE 
guidance. Outside of NICE, there is no independent review of 
findings.  
 
The focus of the ERG’s evaluation of single product 
submissions is on the validity of the underlying clinical claims 
that are made, typically the techniques applied to indirect 
product comparisons, and the structure and assumptions of 
the submitted cost-effectiveness model. The critical questions 
are: (i) whether the evidence submitted conforms to the 
methodological guidelines issued by NICE; (ii) whether the 
company’s interpretation of the evidence is appropriate; and 
(iii) whether there are other evidence sources or alternative 
interpretations that could be useful. In respect of the 
reference case cost-effectiveness model the ERG  is required 
(i) to comment on the robustness and accuracy of the model; 
(ii) the data used to populate the data used to populate the 
mode; and where possible (iii) to carry out a sensitivity 
analysis.  
 
None of the eight STAs reviewed gave any recognition to the 
possibility of modeled claims generating testable predictions, 
as to how possible claims might be evaluated or whether 
recommendations might be revisited if additional evidence 
emerges that challenged the ERG summaries of clinical and 
cost-effectiveness claims. Instead, the focus of the STA is on 
checking and challenging modeled assumptions. These 
challenges range from the choice of clinical data, the 
techniques applied for indirect comparisons on clinical effect, 
the relevance of trial protocols to the target UK population, 
the choice of model, the choice of health states, the state 
transition probabilities, cycle lengths, application of 
survivorship techniques, the measurement of utilities and the 
scope of resource units and costs. The model is checked 
against the gold standard of the reference case.  
 
While standards for developing evaluable predictions, 
falsification and replication are outside the reference case 
remit, three off the products reviewed had the potential for 
generating comparative evaluable claims. These are: alteplase 
for ischaemic stroke; aflibercept for metastatic colorectal 
cancer and ipilimumab for unresectable malignant melanoma 
41 43 47. The models proposed could be modified to generate 
assessable claims, given the expected survival profiles in these 
late-stage interventions at (say) six or 12 months. 
 
Discussion 
There is no doubting the popularity of modeled claims in the 
health technology assessment literature; models which in the 
majority cases conform to the standards proposed in 
checklists such as CHEERS and QHES. Unfortunately, the 
conformity in these models to what are perceived as ‘quality 
standards’, exemplified in the NICE reference case, means (i) 
they fail to meet the standards of normal science and (ii) are 
unlikely, outside of groups such as NICE in the UK, the PBAC in 
Australia, the AMCP in the US and CADTH in Canada to be of 
interest to formulary committees and other health system 
decision makers 48  49  50.  
 
The accepted models can extend, in the case of chronic 
disease, for the lifetime of the patient cohort. Commonly 
applying Markov models or the more mathematically complex 
discreet event modeling, the analyst presents results in terms 
of the recommended gold standard outcome measure of 
lifetime quality adjusted life years saved, claiming benefits 
from one product over another. The models are justified by 
their ability to ‘reflect reality’, a present and future reality of 
‘what is’, in choice of target population characteristics, 
treatment arms, assumed resource utilization and costs and 
outcomes defined by constructed quality of life indices. The 
models rely for their appearance of ‘reasonableness’ on their 
foundation in disparate (yet peer reviewed) literature sources 
and results reported for RCTs. With due account taken in the 
modeling technique of parameter and outcome uncertainty, 
the models are presented as evidence for the comparative 
effectiveness of competing therapies. 
 
Can this practice be justified? Can we make claims for the 
comparative impact of competing products that might extend 
decades into the future and expect them to be taken 
seriously? Could we argue, for example, that the modeled 
claims ‘reflect reality’ and that they should be considered as 
equivalent to modeled claims that generate testable 
hypotheses which can be evaluated from existing evidence; an 
appeal to the facts?   
 
The Standards of Normal Science 
The fact that the modeled or simulated claim is defended on 
the grounds that it ‘reflects reality’ or that it is ‘reasonable’ in 
is representation or correspondence to the target treating 
environment and the anticipated impact of competing 
products and devices in not, unfortunately, a justification for 
accepting the model and claims generated as supporting 
coverage decisions. If a formulary committee is to consider 
modeled claims as a basis for a coverage decision then the 
model claims need to meet the standards of normal science: 
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the claims should be capable of experimental or observational 
evaluation. If not, the model and the claims should be put to 
one side as ‘not fit for purpose’.  
 
If a model is said to ‘reflect reality’ the obvious questions are 
‘what is reality’ and what is a ‘reflection’? From the 
perspective of the model builder (or collaborative group of 
model builders), the reality they perceive is presumably the 
state of things that they think actually exists and are 
‘expected’ to exist over the time frame of the model (an 
imaginary future); their belief in the simulation’s 
correspondence with the real world. If the correspondence is 
sufficient, then the outcomes claimed are necessarily entailed. 
 
Unfortunately, no two groups may share the same vision of 
correspondence with the real world. The NICE Evidence 
Review Group (ERG) may not agree with the manufacturer’s 
submission. Their different realities may generate different 
models which, while subscribing to the same set of standards, 
may result in quite different non-testable claims for the 
superiority of the same competing products. This presents a 
quandary to a formulary committee where competing models 
jostle for attention.  Whose claims should be accepted? 
Should the formulary committee attempt to set ‘acceptable’ 
modeling parameters, as in the NICE reference case, in order 
to ring-fence modeling options?  Even so, there is still the 
possibility that different groups will propose different models. 
Indeed, manufacturers may support competing models that 
meet common standards. Both are justified on the grounds 
that they ‘reflect reality’. Both are defended on the grounds 
that they meet the required standards of the commonly held 
belief system.   
 
Feedback, Information, Evidence 
As noted above, neither the CHEERS nor the QHES checklists 
address the question of whether or not the studies evaluated 
are capable of generating testable predictions. There is no 
concept of how, through evaluating claims, new facts might be 
uncovered. There is also no concept of how claims evaluation 
may generate feedback to formulary committees and other 
health decision makers. The view seems to be that this 
approach is too difficult, time consuming and of little interest 
to decision makers; building imaginary worlds which have little 
if any chance of creating testable predictions is the easy 
option.  
 
Another argument for ‘accepting’ modeled claims even if they 
fail to generate testable hypotheses is that we have limited 
information. Even though the US is well served in access to 
health data, ranging from administrative claims, possibly 
linked to laboratory data, together with electronic medical 
records from in-patient and ambulatory environments, the 
rest of the world is less well served. Our ability to assess claims 
for competing products and devices, particularly if we wish to 
capture patient reported outcomes as a primary endpoint, 
means that we may either to invest significant resources in 
data capture in targeted treatment settings or we have to rely 
on a less resource intensive approach to supporting claims. As 
a result, it could be argued, we fall back to a ‘needs must’ 
justification with our belief in comparative modeled claims 
driving our research agenda and formulary decisions.  
 
The NICE reference case is clearly not designed to generate 
empirically evaluable claims. It rejects the standards of normal 
science. Rather, subject to the ministrations of contracted 
academic assessment centers, manufacturer’s submissions are 
scrutinized; models are tinkered with, adjustments are made 
to cost-per-QALY claims and thresholds re-calibrated. This sets 
the stage for pricing negotiations and agreement on the terms 
for formulary listing – all driven by an imaginary construct 
which, in most cases, is a reformulation of an earlier imaginary 
construct.  
 
NICE arrives at a determination on the acceptability of a 
product, couched in terms of threshold cost-per-QALY 
performance. As these claims for threshold performance are 
impossible to validate, there is little chance that the NICE 
decision can be effectively challenged (other than though 
public opinion and the redoubtable ‘Daily Mail’). Paradoxically, 
while there is presumably evidence to justify building the 
imaginary reference case, there is no appeal to evidence to 
validate claims made. Indeed, the reference case itself 
ensures, whether intentional or not, that the evidence is most 
unlikely ever to eventuate to question NICE decisions. This is 
seen in what Popper refers to as the problem of demarcation 
given the possibility, which distinguishes empirical science 
from pseudoscience, of immunizing any theory against 
criticism 51. 
 
What this process overlooks is the fact, as noted by Popper, 
that never in science are inferences drawn from mere 
observational experience to the prediction of future events 51. 
There is no sense, in these single technology appraisals of any 
interest in (or any commitment to) a program to discover new 
facts.  
 
Equivalent Belief Systems 
There is, however, a school of thought that could, its 
adherents would argue, defend the role of imaginary worlds in 
decision making: relativism. A relativist subscribes to what is 
known as the equivalence postulate.  This postulate holds that 
it is illegitimate to maintain that one belief system is superior 
to another. We cannot argue for ‘superiority’ because we have 
‘good evidence’ for it; in other words, because we have 
validated a belief or claim by an appeal to the evidence. 
Application of the standards of normal science is not, for a 
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relativist, a means of coming to grips with reality. From a 
sociological perspective, for the relativist (or postmodernist) 
to accept the standards of normal science in accepting or 
rejecting claims is to say that one belief system is superior to 
another; a position which is unacceptable if we accept the 
equivalence of all belief system 52. Discovery is put to one side 
in favor of rhetoric, persuasion and authority 53. 
 
For a relativist the focus is on constructing truth 54. If there is a 
group that can convince others of their standards, then they 
have the power to create belief and decide what they would 
label ‘knowledge’.  The result is that modeled claims are not 
subject to the scrutiny that comes from generating and testing 
claims. Hypothesis testing is put to one side. The simulated or 
modeled claim is the end product. 
 
If the objective is to ‘construct truth’ in the choice of model 
and its assumptions, then many of the models reviewed here 
rest on somewhat shaky empirical foundations. Study 
limitations detailed by authors include: limited clinical data, 
lack of clinical follow-up data, inappropriate clinical 
comparator data, lack of data on-follow up or secondary 
therapy choices, lack of data to support modeling state 
transition probabilities, limited direct medical cost data 
(particularly for second-line therapy), lack of indirect cost 
data, lack of non-clinical primary endpoint data (e.g., utility 
scores), reliance on underpowered secondary endpoints from 
clinical studies and an absence of  therapy adherence data. 
Many of these limitations are self-inflicted, due to the long-
term perspective of the model itself and the acceptance that 
the gold standard endpoint is the QALY.  
 
PharmacoEconomics reports that over the past 30 years it has 
published over 3,000 papers. If the proportion of non-
evaluable modeled claims published in the last 12 months are 
indicative of the weight given to those publications, then the 
journal has probably published over one thousand thought 
experiments to support claims for comparative effectiveness 
(not to mention publication of systematic reviews which bring 
in dozens more papers). If this is the case (and given the time 
span involved) a reasonable question might be to ask if any 
author has attempted to revisit modeled claims to evaluate 
whether those claims have been substantiated?  After all, if 
the journal has been prepared to publish, say, a modeled cost-
per-QALY claim for competing products over a 10 year 
timeframe, then it should have been possible in this 
timeframe to revisit this claim. 
 
Acceptance of a belief system, of standards for establishing 
the superiority of comparative product claims that lies outside 
of the standards accepted for normal science, assumes that 
those making formulary decisions share that belief system. 
While this may be true in the UK where NICE and academic 
research groups have embraced the reference case model 
(and indeed these groups were party to its development), in a 
country such as the US there is little evidence for formulary 
committees or other health decision makers agreeing on the 
decision criteria for formulary listing. Given the literally 
thousands of formulary committees that have emerged 
following the passing of the Patient Protection and Affordable 
Care Act in 2010, it is most unlikely that any more than a 
minority are aware (or, at least adhere to)  standards 
proposed by ISPOR and the format for formulary submissions 
recommended by the AMCP. It is even more unlikely that 
there are many that would subscribe to the reference case 
model. They would probably consider it rather odd to base 
decisions for product value on lifetime cost-per-QALY models, 
let alone base decisions on conformity of a claim that is 
patently non-evaluable to a notional threshold value. 
 
The risk, therefore, is that a wider audience, the audience that 
comprises decision makers for pharmaceutical products, fails 
to share the decision standards for modeled claims. The effort 
put into modeling, systematic reviews and organizational 
frameworks may be seen, at best, to be odd, but irrelevant to 
ongoing formulary decisions which seek evidence-based value 
claims and feedback from prior claims for product 
performance.   
 
Rejecting Equivalence 
It is not possible to subscribe to competing belief systems. This 
is an impossible and indefensible position: either subscribe to 
the recognized standards of normal science or admit to 
participating in a pseudoscience. In other words, a 
metaphysical exercise which is intended to persuade rather 
than establish new facts; a belief system, from the relativist 
perspective, which has no claim to superiority over other 
belief systems. The reason for this is quite obvious: if a claim is 
not amenable to empirical testing then we don’t know 
whether it is right or whether it is wrong. It may, to an 
unknown and unknowable extent, be misleading. As such, 
untestable claims should be relegated to the status of 
imaginary worlds or thought experiments; a relegation that is 
effectively summarized in the motto of the Royal Society 
(1660 first meeting; 1662 Royal Charter): nullius in verba (‘take 
no man’s word for it’). 
 
The task of relegating economic evaluations to the category of 
imaginary worlds can be resolved once we abandon attempts 
to apply standards for modeled claims that are inconsistent 
with the standards of normal science. Since the 17th century, 
standards to be applied to modeled claims have been clear-
cut: a model is judged on the basis of the hypotheses or claims 
it creates; its ability to generate new facts.  The first hurdle is 
to agree that the claims are testable, either through 
observation (e.g., an appeal to existing evidence) or through 
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experiment (e.g. an RCT). The second hurdle is to test the 
claim. If the claim is not falsified then it receives provisional 
acceptance. All claims are provisional; subject to further 
evaluations which may overturn them. This process of 
‘conjecture and refutation’, as described by Popper, is at the 
core of the scientific method 55. It supports the notion of 
progress in science. It is a process that explores our 
understanding of the real world and sets the stage for 
generating, testing and the discovery (and exploration) of new 
facts. 
 
Conclusions 
Rejecting or recasting modeled claims that are ‘not fit for 
purpose’ is a necessary step, not only for the formulary 
committee but for other health care decision makers to 
recognize the importance of a firm and defensible evidence 
base for decision making. We can still, of course, subscribe to 
a hierarchy of evidence and work with decision makers to 
identify and, hopefully, close evidence gaps. In recognizing 
that modeled claims may not be fit for purpose does, 
however, raise the issue of whether or not the publication of 
modeled claims which are essentially imaginary worlds or 
thought experiments should be encouraged? Could we argue 
that they are suggestive of more tractable hypotheses, of 
projections, and should be published even if there is no 
assessable hypothesis presented?  In the last resort it is 
presumably up to journal editors and staff to agree on 
whether or not they wish to subscribe to standards which are 
relativistic or culturally determined. Should they support 
postmodernist standards which are clearly at variance with 
those of normal science in publishing claims for comparative 
product performance? Or should they come out and declare 
support for clinical and cost-effectiveness models that drive a 
research agenda that meets the standards of normal science? 
 
The position taken here is unambiguous: if claims based on 
imaginary worlds or thought experiments are published, the 
readership should be advised of this by the authors of the 
paper. This is not to deny the right to publication but merely 
to ensure that the evidence presented is ‘fit for purpose’. If 
the editorial policy of a journal such as PharmacoEconomics is 
to subscribe to and support the beliefs accepted in a discipline 
such as pharmacoeconomics, then this should be made 
explicit, pointing out that these are not the standards of 
normal science.  
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TABLE 1: IMAGINARY WORLDS: ECONOMIC EVALUATION STUDIES PHARMACOECONOMICS JANUARY 2015 TO DECEMBER 2015 
Paper (author) Target Population and 
Intervention 
Sponsor (if any) Modeling Technique and Claims Status Claims Assessment 
and Credibility 
Original Research Article 
Sawyer et al 16 Cost effectiveness of 
sequential biologic 
therapies in patients 
with psoriasis exposed 
to previous biologic 
therapy 
National 
Guideline 
Centre (UK) 
with funding 
from NICE 
A two part model following the NICE 
reference case recommendations with a 
10-year time horizon. Model divided into 
an initial short ‘trial’ period built as a 
simple decision tree and a longer term 
Markov transition model with annual cycles 
and half cycle correctives where patients 
either continue care or drop out and move 
to best supportive care. Outcomes: Cost 
per QALY. Results: Further biologic therapy 
for patients with psoriasis who have 
previously been treated with a biologic may 
be cost effective although considerable 
uncertainty in results. 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a 10-year time horizon 
precludes claims 
assessment 
Blank et al 17  Cost effectiveness of 
prognostic gene 
expression signature 
based stratification of 
early breast cancer 
patients (EPclin) 
Part sponsor 
Sividon 
Diagnostics 
GmbH 
A lifetime Markov state transition model 
with 3 health states (disease free, 
metastasis and death) and a 1-year cycle. 
Comparing standard guidelines with 
guidelines plus molecular tests. Outcomes: 
cost per patient treated and QALYs. 
Results: EPclin strategy was dominant with 
13.173 QALYs and lower costs. [Note: the 
study results support the sponsors 
product]. 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a lifetime horizon 
precludes claims 
assessment 
Mensch 18 Cost-effectiveness of 
rivaroxaban for stroke 
prevention in German 
patients with atrial 
fibrillation 
 A Markov state-transition with 6 health 
states model comparing fixed dose 
rivaroxaban with variable dose warfarin. 
Time line 35 yearas or death for patients 
aged 65 years with monthly cycles. 
Outcomes: cost per QALY. Results: QALY 
adjusted life expectancy for rivaroxaban 
arm 11.06 years vs. 10.35 years for 
warfarin. Corresponding total costs 
€20,238 and €9,464. 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a 35-year time horizon 
precludes claims 
assessment 
Hamid et al 19 Cost-effectiveness of 
BOTOX for 
management of 
Allergan Ltd 
(UK) 
Markov state-transition cost per QALY 
model with 5-year time frame and 6 health 
states. Treatment arms: supportive care + 
No testable 
hypotheses or 
consideration given to 
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urinary incontinence 
with neurogenic 
detrusor overactivity 
BOTOX versus best supportive care alone 
(including anticholinergic drugs ACHDs). 
Cycle length 6-weeks after week 12. 
Outcomes: cost per QALY (including 
reduced frequency of UI).  Results:  BSC + 
BOTOX resulted in an increase in 0.4388 
discounted QALYs gained with an increase 
in costs of £1,689 over 5 years.  [Note: the 
study results support the sponsors 
product]. 
how the claims might 
be evaluated in a 
shorter term model as 
a 5-year time horizon 
precludes claims 
assessment 
Schawo et al 20 Cost-effectiveness of 
methylphenidate 
osmotic-release oral 
systems (OROS) versus 
immediate-release 
methylphenidate (IR) 
in children and 
adolescents with 
ADHD 
Jansse-Cilag BV Markov state-transition model with four 
states with a duration of 12-years. Patients 
entered the model at 6 years of age 
following ADHD treatment guidelines. Cycle 
length of 1-day. Four states were: optimal 
response, suboptimal response, treatment 
stopped and remission (no medication). 
Outcomes: cost per QALY (parent/caregiver 
evaluation). Results: dominance of OROS 
compared to IR. Note: the study results 
support the sponsors product. 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a 12-year time horizon 
precludes claims 
assessment 
Delea et al 21 Cost-effectiveness of 
dabrafenib as first-line 
treatment in BRAF 
V600 metastatic 
melanoma in Canada 
GlaxoSmithKline A 5-year partitioned survival analysis model 
with 3 health states and a cycle length of 1-
week  . Base treatment naïve patients 
comparing dabrafenib, dacarbazine and 
vemurafenib. Time horizon 5-years. 
Outcomes: incremental cost per QALY 
adjusted life year. Results: dabrafenib 
unlikely to be cost-effective compared to 
dacarbazine; no reliable conclusions 
regarding dabrafenib versus vemurafenib 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated although 
the time line for the 
model is only 5 years 
and data accessible for 
2-3 year observational 
study 
Janzic et al 22 Cost-effectiveness of 
novel oral 
anticoagulants 
(NOACs) for stroke 
prevention in atrial 
fibrillation 
 Lifetime state transition Markov model 
comparing dabigatran, rivaroxaban, 
apixaban, high-dose edoxaban with 
standard warfarin treatment. Starting 
cohort 70-years of age with increased risk 
for stroke. Outcomes: cost-per-QALY saved. 
Results: NOACs more likely to be cost-
effective in settings with poor warfarin 
management 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a lifetime time horizon 
precludes claims 
assessment 
Bamrungsawad 
et al 23 
Cost-utility of 
Intravenous 
Immunoglobulin (IVIG) 
 Markov four state-transition model with a 
12-week cycle for the lifetime of patients 
initiating therapy at age of 40 years. 
No testable 
hypotheses or 
consideration given to 
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in steroid-refractory 
dermatomyositis in 
Thailand  
Outcomes: cost-per-QALY saved. Results: 
IVIG dominant 
how the claims might 
be evaluated in a 
shorter term model as 
a lifetime time horizon 
precludes claims 
assessment 
Finkelstein et al 
24 
Cost-effectiveness of 
Qsymia for weight loss 
VIVUS Inc A 56-week trial based estimate of cost and 
QALY outcomes (imputed from SF-12v2). 
Outcomes: Cost per QALY over 1 and 2 
years with residual benefits in years 3 and 
4. Linear regression modeling of change in 
QoL as dependent variable and treatment 
arm. Analogous regressions for PCS and 
MCS scores. Imputed direct costs. Results: 
Qsymia cost-effective at $50.000 threshold. 
May be cost-effective vs surgery if benefits 
associated with therapy extend beyond 
medication cessation.  
Although no testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in an 
observational study, 
the short time-horizon 
makes testing claims 
achievable from 
existing data  
Vestergaard et 
al 25 
Cost-effectiveness of 
competing strategies 
for stroke prevention 
in atrial fibrillation  
 Markov state-transition model to simulate 
costs and outcomes of two treatment 
strategies of guideline adherence versus 
observed treatment strategy over 10-year 
time horizon with a 3-month cycle length 
and a starting age of 70 years. Outcomes: 
cost-per QALY saved over 10 years. Results: 
Guideline adherence was cost-effective. 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a 10-year time horizon 
precludes claims 
assessment 
Takabayashi et 
al 26 
Cost effectiveness of 
proton pump co-
therapy in patients 
taking aspirin for 
stroke secondary 
prevention 
None but 
authorship 
potential 
conflict of 
interest 
Markov state-transition model-based 
simulation of one-year cycle with half-cycle 
correction and a time horizon of 30 years. 
Outcomes: life years gained with 
willingness to pay threshold of US$48,077 
and lifetime risk calculated from probability 
of one health state divided by total of 
probabilities of all health states. Results: 
ASA plus PPI co-therapy cost-effective vs 
ASA in Japan.  
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a 30-year time horizon 
precludes claims 
assessment  
Schremser et al 
27 
Cost-effectiveness of 
epidermal growth 
factor recipient 
receptor (EGFR)-
tyrosine kinase 
inhibitors as first line 
German 
Research Center 
for 
Environmental 
Health 
Markov state-transition model with 3 
mutually exclusive health states with a 
cycle length of 3 weeks and a time horizon 
of 10 years (assumed patient’s lifetime). 
Outcomes: cost-per-QALY. Results: 
Individualized therapy with EGFR likelihood 
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
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therapy with erlotinib 
in advanced lung 
adenocarcinoma 
of 50% cost-effective over standard 
therapy.  
a 10-year time horizon 
precludes claims 
assessment 
Church et al 28 Cost effectiveness of 
falls and injury 
prevention strategies  
 A three-state Markov lifetime transition 
model with a cycle length of 1-year based 
on starting mean age of residents in care 
facilities (84 years). Outcomes: falls 
avoided and QALYs gained. Results: vitamin 
D supplementation, medication review 
multifactorial interventions yield QALYs 
gained and fall averted compared to no-
intervention. In cost-effectiveness terms 
Vitmain D and medication are dominant.    
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model as 
a lifetime horizon 
precludes claims 
assessment 
Gutzwiller et al 
29 
Cost-effectiveness of 
sucroferric 
exyhydroxide(PA21)  
versus sevelamer 
carbonate (SC) in 
patients receiving 
dialysis for 
hyperphosphataemia 
in Scotland 
Vifor Pharma 
Ltd 
Lifetime Markov cohort model to assess 
cost-effectiveness of therapy with PA21 
versus SC with six health states and cycle 
length of 1-month and half-cycle 
correction. Mean age at model entry 56 
years with adopted model lifetime 
represented by a maximum of 44 years 
(528 cycles), corresponding to age 100 
years. Outcomes: undiscounted survival, 
QALYs and cost per QALY gained[Note: Us 
data indicated that for patients with 
dialysis at age 40-44 years expected 
survival 8-years; for those aged 60-64 years 
survival approximately 4.5 years]. Results: 
average base case survival 7.61 years. 
Incremental QALY gain 0.009 QALYS in 
favor of SC strategy and total cost 
difference (in favor of PA21) was £1,609.  
No testable 
hypotheses or 
consideration given to 
how the claims might 
be evaluated in a 
shorter term model. As 
the effective 
observational period 
given average base 
case survival is only 
7.61 years an 
observational study in 
warranted given the 
clinical benefits of 
PA21 (possibly 
combined with SC). 
Systematic Reviews 
Hiligsman et al 
30 
Cost-effectiveness of 
drugs for 
postmenopausal 
osteoporosis 
 The review identified 39 articles that met 
inclusion criteria from 42 articles were that 
assessed using full text. Quality assessment 
followed the CHEERS checklist. All but one 
of the studies used QALYs as the outcome 
with model based cost-effectiveness 
analyses. A Markov cohort model was used 
in 28 studies with 8 studies using a 
microsimulation model and one using a 
discreet-event simulation model. Seven 
studies used a fixed time horizon (3, 5 or 10 
The review did not 
address the issues of 
testable claims, the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary 
committee. 
Application of the 
CHEERS instrument 
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years) with 32 studies using a lifetime 
perspective. Active osteoporotic drugs 
were generally cost-effective when 
compared to no treatment at commonly 
accepted thresholds of around €45,000 per 
QALY gained. It was not possible to make 
recommendations, given heterogeneity of 
studies, on relative cost-effectiveness of 
drugs.   
effectively precluded 
these questions being 
addressed. 
Zhang et al 31 Cost-effectiveness of 
existing treatment 
options for psoriasis 
 The review identified 53 articles that met 
inclusion criteria from 500 articles than 
merited a full text review. Quality 
assessment was evaluated by application of 
the QHES instrument, with the focus on the 
drivers of cost-effectiveness instead of 
cost-effectiveness outcomes. Overall, 11 
studies used a decision tree framework 10 
a Markov model and 7 the York 
(Woolacott)  model i . The authors 
concluded that most cost-effectiveness 
analyses were of low quality – determined 
by short time horizons, not using quality 
adjusted life years as the effectiveness 
measure , failure to include all relevant 
resource units or failing to perform a 
sensitivity analysis.  
The review did not 
address the issues of 
testable claims, the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary 
committee. 
Application of the 
QHES instrument 
effectively precluded 
these questions being 
addressed. 
Srivastava et al 
33 
Humanistic and 
economic burden of 
Chronic Obstructive 
Pulmonary Disease 
(COPD). 
GlaxoSmithKline A total of 32 studies reporting humanistic 
burden and 74 economic burden studies 
were identified with 6 studies reporting 
both. Outcomes in humanistic studies were 
PROs (including HRQoL); the economic 
burden was restricted to cost and resource 
utilization.  
Although focused on 
evidence describing 
and quantifying the 
burden of 
symptomatic COPD  
the review did  not 
address the issues of 
testable claims (e.g., in 
evaluating the burden 
of disease), the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary committee 
in the management of 
gout. 
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Geng et al 34 Cost-effectiveness of 
dideptidyl peptidase-4 
inhibitors for type 2 
diabetes 
 A total of 11 studies met the inclusion 
criteria following full text review of 36 
articles. Quality assessment followed the 
CHEERS checklist. Seven studies used the 
Cardiff Diabetes Model, 3 the UK 
Prospective Diabetes Study (UKPDS) and 
one the Januvia Diabetes Model. Four 
studies were of good quality, six of 
moderate and one of low quality. Four 
studies were based on a lifetime model and  
five based on 40 years. One of the latter 
studies also included 5 years and the 
remaining study 3 years. Seven of the 
studies were funded by manufacturers. All 
studies reported outcomes as QALYs per 
person. 
The review did not 
address the issues of 
testable claims, the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary 
committee.  
Diel et al 35 Cost-effectiveness of 
preventive treatment 
for tuberculosis in 
special high risk 
populations 
 A total of 24 cost-effectiveness studies 
were identified covering six high-risk 
groups. Of these, 20 studies used a Markov 
simulation model and one a decision 
analytic model. QALYs were the outcome 
measure in 15 studies, with TB case 
prevented in 7 studies. Time frames ranged 
from one years to a lifetime. Apart from  6 
studies which did not report a timeframe, 5 
reported a lifetime framework, and 8 
modeled from 20 to 40 years.  
Apart from a brief 
mention of the unlike 
possibility of a long 
term prospective study 
to assess the costs and 
effects of preventive 
treatment, The review 
did not address the 
issues of testable 
claims, the possibility 
of evaluating any 
claims or how the 
claims might be 
evaluated by a 
formulary committee.   
Shields et al 36 Economic and 
humanistic burden of 
gout 
 A total of 39 studies met inclusion criteria, 
17 and 26 respectively were relevant to 
economic and humanistic burden of gout. 
No mention of application of a quality 
checklist. The economic burden was 
restricted to cost studies; the humanistic 
burden on health related quality of life. 
Generic HRQoL measures were most 
frequently reported applied: HAQ-DI (n=6), 
HAQ-II (n=3) and SF-36 (n = 12). Gout 
specific measures; GAQ-GI (n= 2 and GIS 
(n=3).  
Although focused on 
evidence describing 
and quantifying the 
burden of gout, the 
review did  not 
address the issues of 
testable claims (e.g., in 
evaluating the burden 
of disease), the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
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a formulary committee 
in the management of 
gout. 
Zakiyah et al 37 Cost-effectiveness of 
screening diagnosis 
and treatment options 
in pre-eclampsia 
 The review identified 6 studies that met 
inclusion criteria from 8 full text reviews. 
Five of these were economic revaluations 
and one a budget impact analysis. Quality 
assessment was evaluated by application of 
the CHEERS checklist. Four studies used a 
decision model and two a trial based cost 
effectiveness analysis (with 2 studies using 
a 30 year time horizon). No unequivocal 
conclusions could be drawn as to cost-
effective care in pre-eclampsia or the cost-
effectiveness of biomarkers for pre-
eclampsia 
The review did not 
address the issues of 
testable claims, the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary 
committee. Even so, 
the budget impact 
analysis and trial based 
evaluations could have 
been evaluated in 
these terms. 
Poonawalla et 
al 38 
Cost-effectiveness of 
chemotherapeutic 
agents and targeted 
biologics in ovarian 
cancer 
 A total of 73 full text reviews yielded 28 
publications for inclusion. Quality 
assessment used the QHES checklist. 
Covering a period of 18 years (1996-2014) 
made comparisons between studies 
difficult and any consensus. Cost per life 
year gained (LYG) was the outcome 
measure in 15 of the studies; cost per QALY 
gained the outcome in 13 of the studies.  
The range of studies 
included make any 
general conclusion 
difficult. Even so, the 
review did not address 
the issues of testable 
claims, the possibility 
of evaluating any 
claims or how the 
claims might be 
evaluated by a 
formulary committee. 
Review Article 
Fleeman et al 39 Pertuzamab in 
combination with 
trastuzumab and 
docetaxel for HER-2 
metaststic or locally 
recurrent 
unresectable breast 
cancer 
NICE Single 
Technology 
Appraisal 
Roche was asked to submit evidence for 
the clinical and effectiveness of 
pertuzumab + trastuzumab + docetaxel vs. 
placebo + trastuzumab + docetaxel for the 
treatmentof human epidermal growth 
factor in HER-2 metastatic or locally 
recurrent or resectable breast cancer based 
on one ongoing RCT (CLEOPATRA). While 
the ERG judged the trial to be of good 
methodological quality the overall survival 
data were problematic as the trial was 
ongoing. Also, the protocol for the trial did 
not reflect current clinical practice with 
The NICE appraisal 
made no reference to 
the possibility of 
testable claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment. 
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trastuzumab. The cost-effectiveness case 
rested on a lifetime partitioned survival 
model with 3 health states.  Given the lack 
of maturity in the overall survival data 
application of the model was limited. A 
provisional extrapolation by the WERG for 
overall survival yielded a lower survival rate 
and difference between the two arms. The 
estimated ICERs were larger than for the 
manufacturer’s base case. It was deemed 
impossible to set a price for pertuzamab. 
While the Appraisal Committee rejected 
the product a further decision was pending 
at the time of publication 
Greenhalgh et 
al 40 
Eribulin for advanced 
or metastatic breast 
cancer 
NICE Single 
Technology 
Appraisal 
 The NICE appraisal 
made no reference to 
the possibility of 
testable claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment 
Holmes et al 41 alteplase for acute 
ischaemic stroke 
NICE Single 
Technology 
Appraisal 
Boehringer Ingelheim GmbH was asked to 
submit evidence for the clinical and cost-
effectiveness of alteplase for the 
prevention of strokes within a 0 – 4.5 hour 
window from the onset of stroke 
symptoms with the comparator of standard 
medical and supportive management that 
did not include alteplase. A lifetime model 
was utilized generating cost-per-QALY 
estimates as the primary endpoint. The 
ERG generally accepted the clinical claims 
and the modeled cost-effectiveness case. 
Treatment effect was captured by 
modeling the distribution of patients 
between the health states dependent, 
independent, dead at 6 months following 
treatment. Probabilities of transition 
between the health states  beyond 6 
months were modelled from a stroke 
registry, with patients remaining in that 
health state until they experienced a 
recurrent stroke or died. Age specific 
Although there were 
opportunities given 
the structure of the 
modelling to evaluate 
claims at three or six 
monthly intervals, the 
NICE appraisal made 
no reference to the 
possibility of testable 
claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment 
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mortality risk for those without or 
experiencing a recurrent stroke were 
applied. The product was recommended 
for marketing authorization. 
Haas et al 42 Pharmacologic 
management of 
chronic lower back 
pain 
 A total of 7 studies were identified. Two of 
these were modelled studies.  Both scored 
highly on the QHES; other studies were 
considered poor due to lack of good quality 
clinical evidence. Most common outcome 
measures were pain and disability. In the 
two studies that used a reference case 
semi-Markov model the QALYs were 
measured indirectly using a transfer to 
utilities regression equation. Neither model 
specified the ICER timeframe. The authors 
concluded that in the absence of RCT data, 
economic models should be used to 
estimate future costs and outcomes using 
robust methods.  
The review did not 
address the issues of 
testable claims, the 
possibility of 
evaluating any claims 
or how the claims 
might be evaluated by 
a formulary 
committee.  
Wade et al 43 Aflibercept in 
combination with 
irinotecan and FOLFIRI 
for metastatic 
colorectal cancer 
NICE Single 
Technology 
Appraisal 
Sanofi was asked to submit clinical and 
cost-effectiveness evidence for aflibercept 
in combination with irinotecan and 
fluorouracil for treatment of metastatic 
colorectal cancer. The clinical data were 
from one RCT that compared aflibercept + 
FOLFIRI with placebo + FOLFIRI. The RCT 
found a small but significant difference in 
median overall survival and progression 
free survival. The ERG considered the 
manufacturer’s extrapolation of survival 
curves to 15 years to be excessive, instead 
truncating the analysis to 5 years to reflect 
a more realistic survivorship profile. Cost-
effectiveness was based on a 3-state 
Markov model with a 15 year time horizon; 
outcomes were cost-per-QALY. A major 
concern was with the impact of adverse 
events on continuation and HRQoL r The 
ERG defined an alternative base case which 
increased the ICER to £54,368 per QALY. 
The product was not recommended; a 
decision upheld on appeal.  
The NICE appraisal 
made no reference to 
the possibility of 
testable claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment 
Stevenson et al Nalmefene for NICE Single Lundbeck was asked to submit evidence for The NICE appraisal 
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44 reducing alcohol 
consumption 
Technology 
Appraisal 
the clinical and cost-effectiveness of 
nalmefene for reducing alcohol 
consumption in people with alcohol 
dependence. Clinical evidence was from 3 
phase III trials that compared nalmefene 
plus psychosocial support with placebo 
plus psychosocial support. Cost-
effectiveness claims were based on Markov 
cohort model with a timeframe of 5 years. 
The model comprised a one year short 
term phase (cycle length1 month) and a 
long term phase (cycle length 1 year). 
Utility in the first year was from trial-based 
pooled EQ-5D results; in the long term 
utility was assumed to be a function of 
drinking status. The ERG reworked the 
model, in part to draw comparisons with 
the NICE CG15 recommendations for 
psychosocial interventions. Although based 
on limited data (with one comparison 
dropped) the reworked ICERS were little 
different from those first submitted.  The 
methodological issue that had the largest 
impact was the fact that the pivotal RCTs 
did not use the psychosocial support listed 
in the scope. Nalmefene, was 
recommended within its marketing 
authorization, prescribed in conjunction 
with continuous psychosocial support..  
made no reference to 
the possibility of 
testable claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment. 
Fleeman et al 45 Dabrafenib to treating 
unresectable, 
advanced or 
metastatic BRAF V600 
for mutation-positive 
melanoma  
NICE Single 
Technology 
Appraisal 
GlazoSmithkline was asked to submit 
evidence for the clinicakl and cost-
effectiveness of dabrafenib. Although the 
ongoing BREAK-3 trial compared 
dabrafenib with dacarbazine, the Evidence 
Review Group (ERG) considered 
vemurafenib to be the appropriate 
comparator. Evidence for vemurafenib was 
taken from the BRIM-3 trial where the 
comparator was dacarbazine. The company 
presented an indirect treatment 
comparison model that demonstrated no 
clinical difference between the two 
products. The ERG rejected the 
comparison, mainly for the validity of the 
assumptions. This undermined modeled 
The NICE appraisal 
made no reference to 
the possibility of 
testable claims or the 
possibility of 
evaluating claims for 
the comparator 
products in an  NHS 
environment for either 
clinical or cost-
effectiveness claims.   
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claims. The model used to establish cost-
effectiveness had additional issues that 
undermined its credibility. A 30-year 
Markov model was presented with 3 states 
and a cycle length of 1 week. The ERG 
rejected the company’s claims for long-
term survival which were significant in 
making the case for the company’s product 
vs. the comparator. There were limited 
data on HRQoL. The company submitted 
evidence did not conform to the NICE 
methodological guidelines with an 
inappropriate analysis of the evidence. The 
two products were considered to be 
identical in clinical practice    
Simpson et al 46 Sipulencel-T for 
metastatic hormone-
relapsed prostate 
cancer  
NICE Single 
Technology 
Appraisal 
Dendreon, the manufacturer of sipuleucel-
T was asked to submit evidence for clinical 
and cost-effectiveness the product where 
the comparator was abiraterone acetate 
(AA) or best supportive care (BSC). Based 
on the balance of evidence presented, the 
ERG concluded that sipuleucel-T in two of 
three trials improved overall survival but 
none showed prolonged time to disease 
progression. The Advisory Committee 
concluded that the product improved 
overall survival compared to APC-PBO. 
However, in the low PSA-subgroup (which 
was considered the relevant group for 
marketing authorization) there was no 
evidence for superiority in overall survival.  
The company cost-effectiveness model 
considered both the whole population as 
well as subgroups. A lifetime horizon was 
assumed with monthly time cycles with 
parametric survival curves for overall 
survival. The primary outcome was QALYs 
gained. The ERG had a number of concerns 
with the model and undertook a separate 
modelling exercise on a set of nine 
preferred assumptions. The ERGs 
probabilistic sensitivity analysis suggested 
either a zero probability or a very low 
probability of the product meeting a 
The NICE guidance 
recommended against 
the product. The NICE 
appraisal made no 
reference to the 
possibility of testable 
claims or the 
possibility of further 
evaluating claims for 
the product in an NHS 
environment for either 
clinical or cost-
effectiveness claims. 
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£50,000 threshold  
Giannopoulou 
et al 47 
Ipilimumab for 
previously untreated 
unresectable 
malignant melanoma 
NICE Single 
Technology 
Appraisal 
Bristol-Myer-Squibb were asked to submit 
clinical and cost-effectiveness evidence for 
ipilimumab in previously untreated 
advanced melanoma compared to 
dacarbazine (DTIC) and vemurafenib at a 
recommended dose of 3mg/kg. The 
primary source of clinical data was the 
CA184-024 trial which was based on a dose 
of 10mg/kg. Results over a 5-year period 
supported the 10mg/kg dosing in 
demonstrating a significant increase in 
overall survival. The cost-effectiveness 
analysis assumed the equivalence of the 
3mg/kg and 10mg/kg regimen. This was 
questioned as lacking robust evidence 
support together with evidence to inform 
the sequential use of treatment. The 
manufacturer responded with additional 
evidence to support ipilimumab as first line 
therapy. The analyses yielded an ICER of 
£47,900 gained compared to DTIC and 
£28,600 compared with vemurafenib. The 
ERG were concerned with the levels of 
uncertainty associated with both the 
clinical and cost-effectiveness claims. From 
the clinical perspective there was no 
evidence that the dosing regimens were 
equally clinically effective or that 
ipilimumab plus DTIC may be more 
effective than ipilimumab alone.  The cost-
effectiveness analysis applied a semi-
Markov model with ipilimumab as first line 
therapy, second-line active therapy and 
third line best supporting care. The ERG 
was critical of the lack of data to support 
the sequencing outcomes modeled and 
suggested a first-line model only to be 
more appropriate. Even then, there was 
considerable uncertainty. This uncertainty 
was not resolved for the ERG in the 
manufacturer’s further response to the 
Appraisal Committee’s initial decision and 
NICE recommendation for recommending 
the product only in the context of research 
Although the ERG 
admitted considerable 
uncertainty with 
respect both to clinical 
claims for equivalence 
in dosing and in 
combination therapy 
together with the lack 
of clinical evidence to 
support treatment 
sequencing,  Even with 
the short survival time 
frames with 
unresectable 
melanoma the NICE 
appraisal made no 
reference to the 
possibility of testable 
claims or the 
possibility of 
evaluating claims for 
the product in an NHS 
environment for either 
the clinical or cost-
effectiveness claims.  
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as part of a clinical study.  Marketing 
approval was finally given after a discount 
was agreed with the manufacturer under 
the market access scheme. IT was admitted 
that there were concerns that the appraisal 
process was initiated before there was 
sufficient evidence to inform the cost-
effectiveness assessment.  
 
 
                                                 
 
